

# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address COMMISSIONER FOR PATENTS FO Box 1430 Alexandria, Virginia 22313-1450 www.tepto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/824,124	04/13/2004	John F. Shanley	CMI500IUSCNT7	6433
49/27 7590 09/19/2008 Intellectual Property Department CONOR MEDSYSTEMS, INC. 1003 HAMILITON COURT			EXAMINER	
			BUL, VY Q	
MENLO PAR			ART UNIT	PAPER NUMBER
			3773	
			MAIL DATE	DELIVERY MODE
			09/19/2008	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

## Application No. Applicant(s) 10/824,124 SHANLEY, JOHN F. Office Action Summary Examiner Art Unit Vv Q. Bui -- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --Period for Reply A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS. WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION. Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b). Status 1) Responsive to communication(s) filed on 30 July 2008. 2a) ☐ This action is FINAL. 2b) This action is non-final. 3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213. Disposition of Claims 4) Claim(s) 1-4 and 6-17 is/are pending in the application. 4a) Of the above claim(s) \_\_\_\_\_ is/are withdrawn from consideration. 5) Claim(s) \_\_\_\_\_ is/are allowed. 6) Claim(s) 1-4 and 6-17 is/are rejected. 7) Claim(s) \_\_\_\_\_ is/are objected to. 8) Claim(s) \_\_\_\_\_ are subject to restriction and/or election requirement. Application Papers 9) The specification is objected to by the Examiner. 10) The drawing(s) filed on is/are; a) accepted or b) objected to by the Examiner. Applicant may not request that any objection to the drawing(s) be held in abevance. See 37 CFR 1.85(a). Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d). 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152. Priority under 35 U.S.C. § 119 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some \* c) None of: Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). \* See the attached detailed Office action for a list of the certified copies not received. Attachment(s) 1) Notice of References Cited (PTO-892) 4) Interview Summary (PTO-413) Paper No(s)/Mail Date. Notice of Draftsperson's Patent Drawing Review (PTO-948)

Paper No(s)/Mail Date \_

3) T Information Disclosure Statement(s) (PTO-1449 or PTO/SD/06)

6) Other:

Notice of Informal Patent Application (FTG-152).

Art Unit: 3773

#### DETAILED ACTION

#### Claim Rejections - 35 USC § 102

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless -

- (e) the invention was described in (1) an application for patent, published under section 122(b), by another filled in the United States before the invention by the applicant for patent or (2) a patent granted on an application for patent by another filled in the United States before the invention by the applicant for patent, except that an international application filled under the treaty defined in section 351(a) shall have the effects for purposes of this subsection of an application filled in the United States only if the international application designated the United States and was published under Article 21(2) of such treaty in the English language.
- (e) the invention was described in a patent granted on an application for patent by another filed in the United States before the invention thereof by the applicant for patent, or on an international application by another who has fulfilled the requirements of paragraphs (1), (2), and (4) of section 371(c) of this title before the invention thereof by the applicant for patent.

The changes made to 35 U.S.C. 102(e) by the American Inventors Protection Act of 1999 (AIPA) and the Intellectual Property and High Technology Technical Amendments Act of 2002 do not apply when the reference is a U.S. patent resulting directly or indirectly from an international application filed before November 29, 2000. Therefore, the prior art date of the reference is determined under 35 U.S.C. 102(e) prior to the amendment by the AIPA (pre-AIPA 35 U.S.C. 102(e)).

Claims 1-4, 6-9 and 17 are rejected under 35 U.S.C. 102(e) as being anticipated by Her et al-6.033.433.

As to claims 1-4, 6-9 and 17, Ehr-'433 (please refer to a portion of Fig. 30 reproduced on next page) discloses a stent having S-shape bridging elements crossing three times at locations B. C. D the midlines AE of V-shapes as recited in the claims. Art Unit: 3773



Fig. 30

Art Unit: 3773

#### Claim Rejections - 35 USC § 103


The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior at are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

Claims 10-16 are rejected under 35 U.S.C. 103(a) as being unpatentable over Fischell et al.-5,697,971 in view of Jang-6,235,053.

As to claims 10-16, Fischell-'971 (Figs. 2-3) discloses a stent 10 having cylindrical tubes having adjacent struts and S-shaped bridging elements substantially as recited in the claims, except for the connecting points of the S-shaped bridging elements located diagonally and bridging element less wider than strut as recited in the claims. However, Jang-'053 (Fig. 1-3, for example) discloses connecting points of the S-shaped bridging elements located diagonally (off-center connection) and S-shaped bridging elements less wider than adjacent struts. It would have been obvious to one of ordinary skill in the art at the time of the invention to move the connecting points to the locations as shown in modified Fischell-'971 stent in view of Jang-'053 (please, see Fig. 2 on next page) for this modified configuration provide Fischell-'971's S-shaped bridging elements longer, more flexible and having more stored length for expansion.

Art Unit: 3773



Art Unit: 3773

### Response to Arguments

Applicant's arguments filed 4/25/2008 have been fully considered but they are not persuasive.

The arguments suggested that the Ehr-'433 does not meet the recitation "a midline parallel to the longitudinal axis of the stent" as now recited in the independent claims.

However, the stent is basically of a cylindrical form, therefore midline AE as shown in above Her-'433's Fig. 10 is indeed parallel to the longitudinal axis of the stent as recited in the claims.

In short, the limitation added to the independent claims does not clearly define the present invention over the Ehr-433 reference.

#### Conclusion

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Vy Q. Bui whose telephone number is 571-272-4692. The examiner can normally be reached on Monday-Tuesday and Thursday-Friday.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Jackie Ho can be reached on 571-272-4696. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

/Vy Q. Bui/ Primary Examiner, Art Unit 3773